NMD develops medical treatment for diseases of the muscles and nerves, which in the future may be of great importance to patients with chronic musculoskeletal disorders such as Myasthenia Gravis and amyotrophic lateral sclerosis (ALS).

In patients with diseases of the muscles and nerves, the loss of muscle functionality results in reduced mobility and the ability to manage themselves in everyday life, and many experience greatly reduced quality of life. In the severely affected patients, muscle weakness can lead to life-threatening respiratory problems. There are currently few treatment options for these diseases and they have significant side effects.

It is NMD Pharma’s vision to improve the quality of life and survival of patients with diseases of the muscles and nerves. The company is developing new treatments that strengthen neuromuscular transmission and muscle function in patients and have fewer side effects than the products available today.

It is estimated that there is a total market potential of approx. USD 1 billion for the new drug.

What has been accomplished?
NMD Pharma expects to be able to launch the first clinical trials during 2020.

External investors

Novo Seed, Lundbeck Emerge, INKEF Capital, Roche Venture Fund, Jeito Capital.

Founded in 2015

Have a look at some of our other companies

Read more about some of our other companies that are on their way to the top and others that have already made it.

Our current companies

Explore our entire portfolio

Success Stories

Companies that went all the way